title: Neramexane (merz pharmaceuticals/forest laboratories).
abstract: Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
authors.affiliation: Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. rammes@mpipsykl.mpg.de
authors.forename: Gerhard
authors.initials: G
authors.lastname: Rammes
authors.forename: Anja
authors.initials: A
authors.lastname: Schierloh
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D003517:Cyclopentanes; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; C114144:neramexane